GLUE
Monte Rosa TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
GLUE vs peer average
54/100
GLUE vs. peer average (C vs. C)
Grade spread
B 3 · C 2 · D 6
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ANAB is the first available peer comparator.
Small-cap biotech peer where valuation is driven mostly by clinical execution, program breadth, and cash runway rather than current earnings.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
GLUE
Monte Rosa Therapeutics
ANAB
AnaptysBio
Grade
C
B
Momentum
92
83
Value
49
41
Sentiment
30
51
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Constructive
Grade position vs ANAB
GLUE / ANAB
Grade Position
In line
GLUE vs. peer average (C vs. C)
54/100
Momentum
92
GLUEValue
49
GLUESentiment
30
ANABRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs GLUE
ANAB is the first peer returned for this comparison set.